Artiva Biotherapeutics, Inc.
No enriched coverage for $ARTV in the last 7 days.
Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 artv-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®’s potential to drive deep B-cell depletion
RA CAPITAL MANAGEMENT, L.P. purchased 45,768 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $9.96 ($9.93–$9.99, $0.46M total) across 2 trades over 2026-07-29 to 2026-07-31.
RA CAPITAL MANAGEMENT, L.P. purchased 41,319 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at $9.99 ($0.41M total) on 2026-07-24.
Recent ARTV coverage spans insider activity, earnings and financial news.
In the last 30 days, ARTV insiders filed 3 SEC Form 4 transactions — 2 purchases ($456K) and 1 sale ($5K). The most active reporter was RA CAPITAL MANAGEMENT, L.P. with 2 filings. 33% of those filings were made under pre-arranged Rule 10b5-1 plans.
The filing adds concrete regulatory and clinical-development milestones alongside a large cash balance, improving visibility into the Phase 3 timeline and funding runway.
This is a disclosed insider-adjacent fund purchase, but it is not a company fundamental update; it may slightly affect near-term sentiment/liquidity expectations.
The Form 4 shows a director/10% owner indirect buy, which can be read as incremental confidence but is not a fundamental catalyst by itself.
Major-holder buying may support near-term sentiment, but it is not a fundamental catalyst like earnings or guidance.
This is a disclosed insider-style accumulation by a large holder, but it is indirect and not tied to a 10b5-1 plan, so it may be read as incremental bullish sentiment.
alphai scores every news story that mentions ARTV with an AI model for sentiment and relevance, and aggregates insider trades from Artiva Biotherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Artiva Biotherapeutics, Inc. (ARTV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 artv-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Artiva Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®’s potential to drive deep B-cell depletion
6 min readRA CAPITAL MANAGEMENT, L.P. purchased 45,768 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $9.96 ($9.93–$9.99, $0.46M total) across 2 trades over 2026-07-29 to 2026-07-31.
2 min readRA CAPITAL MANAGEMENT, L.P. purchased 41,319 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at $9.99 ($0.41M total) on 2026-07-24.
2 min readA roundup of SEC-reported insider trades for US-listed firms. RA Capital Management bought about $2.58M of Artiva Biotherapeutics (ARTV). Byrna Technologies (BYRN) saw board chair and CEO buy about $179k and $77k. Aqua Capital bought about 120k Energizer (ENR) shares. StoneX (SNEX) insiders sold about $7.8M, $3.89M, and $7.13M. CoreWeave (CRWV) CEO sold about $24.1M under a 10b5-1 plan; Travelers (TRV) CFO sold about $6.01M.
4 min readRA CAPITAL MANAGEMENT, L.P. purchased 264,586 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $9.76 ($9.55–$9.96, $2.58M total) across 3 trades over 2026-07-21 to 2026-07-23.
2 min readRA CAPITAL MANAGEMENT, L.P. purchased 160,354 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $8.93 ($8.93–$8.95, $1.43M total) across 2 trades over 2026-07-16 to 2026-07-17.
2 min readRA CAPITAL MANAGEMENT, L.P. purchased 21,654 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $8.96 ($8.94–$8.97, $0.19M total) across 2 trades over 2026-07-10 to 2026-07-13.
1 min readRA CAPITAL MANAGEMENT, L.P. purchased 32,876 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $8.89 ($8.88–$8.98, $0.29M total) across 2 trades over 2026-06-25 to 2026-06-26.
2 min readRA CAPITAL MANAGEMENT, L.P. purchased 531,326 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $8.66 ($8.57–$8.99, $4.60M total) across 3 trades over 2026-06-12 to 2026-06-16.
2 min readRA CAPITAL MANAGEMENT, L.P. purchased 1,027,722 indirectly-held shares of Artiva Biotherapeutics, Inc. (ARTV) at an average of $7.44 ($6.91–$7.91, $7.65M total) across 3 trades over 2026-06-09 to 2026-06-11.
2 min read